Denali Capital Acquisition Corp.
DECAW
NASDAQ Global Market0.04
USD
+0.00
- -
CIK
0001913577
ISIN
KYG6256B1142
Return %
Stock
S&P500
1Y
-22.40
18.21
3Y
-22.40
63.29
5Y
-61.20
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Lei Huang
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 437 Madison Avenue New York City NY United States of America 10022
- IPO Date
- May 31, 2022
- CIK
- 0001913577
- Similar Companies
- Business
- Denali Capital Acquisition Corp. (NASDAQ: DECAW) is a blank check company, or special purpose acquisition company (SPAC), incorporated in the Cayman Islands in 2022 and headquartered at 437 Madison Avenue, 27th Floor, New York, New York. The company has no significant operations and focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting entities in the technology, consumer services, and hospitality sectors; it offers no current products or services beyond its SPAC structure, including Class A ordinary shares, warrants, and units traded on Nasdaq and OTC Markets. Geographically, it operates principally from the United States with a focus on North American and global merger targets. In September 2025, Denali completed a business combination with Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company focused on non-opioid pain therapies including SP-102; the transaction, originally announced in August 2024 and amended multiple times through July 2025, resulted in Denali's domestication to Delaware, renaming to Semnur Pharmaceuticals, Inc. (OTC: SMNR, SMNRW), and issuance of new common shares, preferred shares, and warrants valued at approximately $2.5 billion in merger consideration; prior to closing, Denali extended its combination deadline multiple times into 2025 via trust deposits funded by convertible promissory notes to Scilex, and filed an effective S-4 registration statement with the SEC, approved by shareholders on September 3, 2025.